贝维菲巴提德:首次获得批准
1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.
Drugs
|February 12, 2026
概括
贝维菲巴提德是一种糖蛋白IIb/IIIa对抗剂,现在已在中国批准用于经过皮肤冠状动脉干预的急性冠状动脉综合征患者. 这种治疗旨在减少诸如支架血栓形成和血流减缓等风险.
科学领域:
- 心血管药理学心血管药理学
- 整合素受体对抗性 整合素受体对抗性
背景情况:
- 贝维菲巴提德是一种循环七环抗体,向糖蛋白IIb/IIIa和αvβ3整合素受体.
- 它是由Bio-Thera Solutions开发的,用于治疗急性冠状动脉综合征 (ACS).
研究的目的:
- 总结贝维菲巴提德的开发里程碑,导致其获得监管批准.
- 突出贝维菲巴提德在通过皮肤冠状动脉干预 (PCI) 后减少并发症方面的作用.
主要方法:
- 审查贝维菲巴提德的发展途径.
- 分析其作为GP IIb/IIIa抗剂的作用机制.
主要成果:
- 贝维菲巴提德于2024年6月25日在中国获得批准.
- 已批准用于需要PCI的ACS患者,以减轻急性闭塞,支架血栓形成,没有再流和血流缓慢等风险.
- 第一次批准是作为PCI,抗血小板和抗凝固剂治疗的辅助疗法.
结论:
- 贝维菲巴提德的批准标志着ACS治疗的重大进展.
- 它提供了一个新的治疗选择,以改善接受PCI的患者的治疗结果.
- 降低血栓并发症的药物的有效性是关键的好处.
相关概念视频
FDA Approved Drugs: Changes to Approved Drugs
275
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
275
Obedience
35.7K
According to obedience research, we may harm others under the forceful pressures of an authority figure (Milgram, 1974). How about if the inappropriate orders were delivered with less force? The increasing interdependence between nurses and physicians compelled Hofling and his colleagues to explore nurses’ reactions to a potentially harmful medical request made by the perceived authority figure, the doctor (Hofling, Brotzman, Dalrymple, Graves, & Pierce, 1966). In this situation,...
35.7K
Ethics in Research
25.8K
Today, scientists agree that good research is ethical in nature and is guided by a basic respect for human dignity and safety. However, this has not always been the case. Modern researchers must demonstrate that the research they perform is ethically sound.
25.8K


